论文部分内容阅读
NO.01以岭药业(002603)创新型中药和中药国际化的引领者,心脑血管药物通心络、参松养心胶囊、芪苈强心胶囊等2016年上半年销售近14亿元;抗感冒复方中药莲花清瘟,2016年上半年销售增长50%左右,并且进入美国FDA二期临床。公司并已通过增发募资布局化学制剂出口。公司自2011年上市以来发
NO.01 Yiling Pharmaceutical (002603) The pioneer of innovative Chinese medicine and internationalization of Chinese medicines, cardiovascular medicine Tongxinluo, Shensong Yangxin Capsule and Qili Qiangxin Capsule sold nearly RMB 1.4 billion in the first half of 2016, ; Anti-cold compound Chinese lotus Qingwenwen, sales growth of about 50% in the first half of 2016, and entered the United States FDA Phase II clinical. The company has also been through the additional fund-raising distribution of chemical exports. The company has been listed since listing in 2011